Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Andrew B Lassman, MD
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02238496CT.gov Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | — | Completed | — | — | — |
NCT01051557CT.gov Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma | — | Completed | — | — | — |
NCT00112736CT.gov Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anaplastic Oligodendroglioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Temsirolimus (this asset) | Andrew B Lassman, MD | P1/2 | B · 62 |
| Cediranib | National Cancer Institute (NCI) | P2 | BBB |
| Irinotecan | City of Hope Medical Center | P2 | BB |
| Trametinib | Novartis Pharmaceuticals | P4 | BB |
| Carboplatin | Oliver Jonas | P2 | BB |
| Camustine | Shandong Lanjin Pharmaceuticals Co.,Ltd | P3 | BB |
| Dabrafenib | Novartis Pharmaceuticals | P4 | BB |
| Ziv-Aflibercept | National Cancer Institute (NCI) | P2 | B |
| Perifosine | Andrew B Lassman, MD | P1/2 | B |
+42 more in the Anaplastic Oligodendroglioma cohort
Other indications for Temsirolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gliosarcoma | — | P2 | BBB · 74 |
| Adult Glioblastoma | — | P2 | BBB · 74 |
| Giant Cell Glioblastoma | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Temsirolimus in Anaplastic Oligodendroglioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/temsirolimus-anaplastic-oligodendroglioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →